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Introduction
Calcium is a major secondary messenger with significant roles in many cellular
processes (1) :
 muscle contraction
 gene transcription
 Cell Proliferation & death (2)
 Ca levels and signaling alterations (in cancer cells) could sense with Ca-binding
proteins such as: S100 proteins (1) (were named s100 for their ability to be soluble
in 100 % ammonium sulfate(17).
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Introduction
General characteristics of S100 proteins family:
 24 members (1)
 On chromosome one (1).
 In Ca presence : heterotrimer , otherwise: heterodimer , (2).
 Some S100s also could bind to zinc & copper (1).
 intracellular Ca     Ca interaction with S100s via EF domains (in C-ter) 
conformational rearrangement of s100  expose their hydrophobic patches
interaction with target proteins (1,6).
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Introduction
Intracellular functions of S100s (6) :
 ca homeostasis regulation 
 protein phosphorylation
 various enzyme activities regulation
 Cytoskeletal rearrangement
 transcriptional activities
Extracellular functions S100s (6):
 cell proliferation
 Apoptosis
 chemotaxis 7
Introduction
8Leclerc1 & et al 2011 (10)
Introduction
E. Leclerc et al (2009)(2).
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structure and function
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3members of the S100s : A8, A9, and A12:
 high amounts constitutively expression in neutrophils and are inducible in 
macrophages (6).
 Overexpression in acute & chronic inflammatory disorders  mentioned as : 
“inflammation-associated S100s“ or “calgranulins” (6).
 Interaction with “alarm” receptors (such as TLRs & RAGE ) extracellular pro-
inflammatory effects   DAMP molecules(6).
 A8 & A9: 40% of neutrophil cytosolic proteins & release by activated neutrophils
(6).
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structure and function
Calprotectin: 
 A Heterodimer of S100A8 and S100A9 (1) 
 two EF-hand Ca-binding domains (5,6)
 A8:
93 amino acid length
10.8 kDa (3).
significant in fetus development and life (A8 was knocked out mice fetus 
death(2)).
 A9 :
114 amino acid length
13.2 kDa (3).
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M. Pruenster et al. (2016)(13)
structure and function
13
Markowitz & Carson (2013)(14)
structure and function
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M. Pruenster et al. (2016)(13)
structure and function
S100A8 and S100A9 also constitutively are co-expressed in :
 Neutrophil ,  myeloid DC,   Platelets ,   osteoclasts,    hypertrophic 
chondrocytes (6).(not constitutively by macrophages and endothelial 
cells (5) ). 
o In inflammation: also release from epithelial cells and keratinocytes (2)
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structure and function
Calprotectin Receptors:
 TLR-4(1,2)
 RAGE(1,2)
 EMMPRIN (1).
 Scavenging Receptors; CD36 (1,2).
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structure and function
Leclerc.E, et al 2009 (2)
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Binding sites of RAGE receptor
structure and function
18
Types of RAGE Isoforms
Bongarzone & etal , 2017(9)
structure and function
19
Ehrchen & etal 2009
TLR-4 Receptor
structure and function
Biological functions of A8/9 heterotetramer :
 Myeloid differentiation
 Inflammation & Inflammatory diseases: (RA,CF, Crohn, ..).
 Antimicrobial activity
 cancers such as: Colon, prostate and gastric, .. (2).
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structure and function
Roles in Cancers
o In cancers: TNFα, TGFβ and VEGF-A  induce S100A8/A9 production (4) 
regulate growth (2) , development , and metastasis of tumor cells (1,4). 
o S100A9 can be used as a sensitive and specific marker for the activity of MDSCs 
reflecting the growth & metastasis of tumors (4).
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structure and function
Pro-inflammatory Roles :
due to LPS and TNF- induce (6):
 LPS and IL-1 murine endothelial cells stimulation  S100A8 and S100A9 
(5).
 LPS, IFN-, IL-1, and TNF-  murine macrophages stimulation S100A8 
expression (not A9) (5).
 S100A8/A9 in keratinocytes and neutrophils binds polyunsaturated fatty acids 
including oleic, linoleic, … which are precursors of mediators involved in 
inflammation and gene regulation (6).
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structure and function
Roles in Chemotaxis
 A9 and A8/A9 release by neutrophils monocyte trans-endothelial migration(5).
 Murine S100A8 is chemotactic for neutrophils and monocytes (5)
 A8 & A9  neutrophil migration in a murine model of acute gouty arthritis (5).
 ID injections of murine A8 and human  A8, A9, & A8/A9 into mice 
accumulation of neutrophils & leukocyte migration to inflammatory sites (5). 
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structure and function
Microbial Growth Inhibition
 microbial infections releasing the cytokines such as: IL-1, IFN-, and TNF- 
by abnormally differentiated keratinocytes S100A8 &  S100A9  (6).
A8 & A9 inhibit the microbial growth by:
 chelating zinc  inhibit bacterial adhesion to mucosal epithelial cells
Bacterial growth (an innate immune responses)(5).
24
structure and function
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Signaling Pathway
“Leclerc & etal 2015”(1)
26
signaling pathway
27
(Zheng & etal 2015(4))
 Sorci & etal 2013 (7).
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RAGE activates various signaling pathways
signaling pathway
29
Leclerc1 & etal 2011 (10)
signaling pathway
 S100A8/A9 bind to RAGE  NF-κB and MAPK activation  tumor growth
 1. In colorectal tumors, A8/A9      expressing carboxylated glycans on tumor cells  NF-κB
activation cell proliferation (4).
 2. In colon tumor cells S100A8/A9 interacted with RAGE  activation of MAPK and NF-κB
 activated the expression of pro-tumorigenic gene. and the growth and metastasis of colon 
tumors was reduced in RAGE- and S100A9-deficient mice(4).
 3. In gastric cancer, exogenous S100A8/A9 activated p38MAPK and NF-κB  up regulated 
metal matrix metalloproteinase 2 and 12  promoted the metastasis and invasion of tumor 
cells (4).
 In addition, tumor cells could acquire pseudopodia for invasion via activating MAPK p38 (4).
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signaling pathway
diseases
31
diseases
Ehrchen & etal 2009(8)
32
diseases
33
Leclerc1 & etal 2011 (10)
diseases
34
Markowitz & Carson (2013)(14)
diseases
S100A8/A9  increase the:
 colon- and breast-cancer cells proliferation in mouse (via RAGE) (1).
 cell migration and cancer progression in pancreatic cancer (1)
 A8/9 bind with RAGE  tumorogenesis of colon cancer (in mice) (1).
 A8 & A9  reacted with TLR-4 (on T CD8+)  IL17 expression  systemic 
autoimmune responses in murine SLE model (4).
35
diseases
 A8 bind to TLR-4  osteoclasts formation  actin ring formation in 
osteoclasts antigen-induced arthritis (AIA) (destruction and resorption of bone) 
in murine model (4).
 A8  local vascular penetration  helps to lung metastatic cells (1).
 A9 bind to TLR-4  Prostate tumor growth (1). 
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diseases
 in serum:  various infections and inflammatory pathologies such as cystic 
fibrosis, tuberculosis, and juvenile rheumatoid arthritis  circulating 
neutrophils A8/A9 in serum (1 g/ml) .
 in the synovial fluid and plasma : in rheumatoid arthritis and gout.
 Local secretion : in periodontal infections and in experimental murine
abscesses (5).
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diseases
38
Bresnick et al 2015)(15)
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Bresnick et al 2015(15)
diseases
40
41
 Journal name: Inflammation Research /2018/ Italy/IF:2.1.
 Psoriasis is an inflammatory and chronic skin disease.
 Onset & progression reason
pro-inflammatory cytokines including :TNF, IFN-γ, IL-17, IL-22, IL-
23, IL-12 and IL-1β production by Th1, Th22 and Th17.
The interaction among dendritic cells, keratinocytes, neutrophils and 
pro-inflammatory cytokines.
 Skin bipsies prepared from 3 groups:
 1.healthy
 2.Patient who treated with cytokines inhibitor drugs (adalimumab, 
etanercept and ustekinumab)
 3.patient who treated with any drug. 42
 Biopsies were stained with anti S100A8 AND S100A9 antibodies and 
colour intensity assessed by microscope (immunohistochemical
analysis). 
 Results : 
Colour intensity (A8/A9 contents) (clinical symtoms) is higher in 
patient who treated with any drug than Patient who treated with 
cytokines inhibitor drugs, and both are higher than healthy 
participants.
 Reduction of Cytokines such as TNF , IL-12 , IL-23  A8/A9 
Reduction  clinical & immuno histochemical signs Reduction. 43
44
Reduction of PASI (Psoriasis area Severity Index) ==> Reduction of Immuno staining severity 
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 Journal name: Arthritis Research & Therapy /2017/ Netherlands 
/IF:4.1. 
 Method:
 1. CiOA (collagenase-induced OA) was induced by injection of 
collagenase into knee joints of wild-type C57BL/6 (WT), and S100a9-/-
mice.
2. Intra-articular injection of S100A8.
3. expression of monocyte markers, pro-inflammatory cytokines, and 
chemokines was determined in the synovium using ELISA and RT-
qPCR.
4.Cells were isolated from the bone marrow (BM), spleen, blood, and 
synovium and monocytes were identified using FACS. 46
 Results:
 WT : expression of Ly6c(high) monocytes (CCR2+)  Inflammation
 S100A9 -/- : expression of Ly6c(low) monocytes (CX3CR1+)  tissue 
repair roles.
 A 14% decrease in myeloid cells was found in WT BM at CiOA d7.
 No decrease in myeloid cells in S100a9-/- BM was found, suggesting that 
S100A8/A9 promotes the release of myeloid populations from the BM.
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 Journal name: Biochimica et Biophysica Acta/2016/Taiwan/IF:3.6.
 Modeling of S100A9 & CHAPS (3-[(3-cholamidopropyl) 
dimethylammonio]-1-propanesulfonatevia HADDOCK (2000 models).
 Selection 200 model with lower energy levels.
 Selection 10 models via PROCHECK.
 Identification of active & passive residue via NACCESS.
 Final structure was shown via PYMOL.
 Molecular dynamics simulation via AMBER.
 Effects on cell proliferation via WST-1 assay.
 Results were shown that CHAPS had anti-prolifrative effect on cells, via 
inhibition of S100A9 & RAGE V domain complex formation.
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